Kestra Medical Technologies (KMTS) Cash & Equivalents (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Cash & Equivalents data on file, last reported at $291.3 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $291.3 million, up 435.99% year-over-year; the trailing twelve-month figure through Jan 2026 was $291.3 million (up 435.99% YoY), and the FY2025 annual result was $237.6 million, up 2780.29% from the prior year.
• Cash & Equivalents grew to $291.3 million in Q1 2026 per KMTS's latest filing, from $175.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $291.3 million in Q1 2026 and troughed at $8.2 million in Q2 2024.
• A 3-year average of $128.9 million and a median of $100.0 million in 2024 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 2780.29% in 2025 and fell as far as 101.28% in 2025.
• A 3-year view of Cash & Equivalents shows it stood at $76.9 million in 2024, then surged by 128.07% to $175.4 million in 2025, then soared by 66.07% to $291.3 million in 2026.
• Business Quant data shows KMTS's Cash & Equivalents at $291.3 million in Q1 2026, $175.4 million in Q4 2025, and $201.2 million in Q3 2025.